 |
|
|
| |
Long-Term Follow-up of Patients with Chronic HCV and F2-F3 Fibrosis After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry
|
| |
| |
Reported by Jules Levin
Digestive Disease Week
02nd - 05th June, 2018 Washington, D.C
1Jacobson, Ira M.; 2Zeuzem, Stefan; 3Gane, Edward; 4Buti, Maria; 5Gordon, Stuart C.; 6Sulkowski, Mark S.; 7Cheinquer, Nelson; 7McNabb, Brian; 7Chen, Frances; 7Dvory-Sobol, Hadas; 7Osinusi, Anu; 7Brainard, Diana; 7Subramanian, Mani; 8Ramji, Alnoor; 9Agarwal, Kosh; 10Reddy, K. Rajender; 11Bourliere, Marc
1New York University School of Medicine, New York, NY, United States; 2Johann Wolfgang Goethe-Universität, Frankfurt, Germany; 3New Zealand Liver Transplant Unit, Auckland, New Zealand; 4Hospital Universitario Vall d'Hebron, Barcelona, Spain; 5Henry Ford Health System, Detroit, MI, United States; 6Johns Hopkins University School of Medicine, Baltimore, MD, United States; 7Gilead Sciences, Foster City, CA, United States; 8University of British Columbia, Vancouver, BC, Canada; 9Kings College Hospital NHS Trust Foundation, London, United Kingdom; 10University of Pennsylvania, Philadelphia, PA, United States; 11Hôpital Saint-Joseph Marseille, Marseille, France
1.Xu F, et al. Clin Infect Dis 2016;62:289-97.
2.Bourlière M, et al. AASLD 2017, poster 969.c
Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry - (11/27/17)
|
| |
|
|
|
|
|
